

Anita Deswal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5338012/publications.pdf>

Version: 2024-02-01

169
papers

13,514
citations

31976

53
h-index

22166

113
g-index

183
all docs

183
docs citations

183
times ranked

13740
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2022, 97, 411-420.	4.1	11
2	Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment. <i>Current Oncology Reports</i> , 2022, 24, 543-553.	4.0	15
3	The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. <i>Cancers</i> , 2022, 14, 1304.	3.7	17
4	Acute coronary syndrome in patients with cancer. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 275-290.	1.5	4
5	Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 315-330.	1.6	7
6	Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 599-606.	4.8	1
7	Myocardial Dysfunction in Patients with Cancer. <i>Heart Failure Clinics</i> , 2022, 18, 361-374.	2.1	1
8	Isolated Cardiac Amyloidosis: An Enigma Unravelling. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 11, 53.	1.0	4
9	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Arthritis and Rheumatology</i> , 2021, 73, 866-874.	5.6	56
10	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. <i>Journal of the National Cancer Institute</i> , 2021, 113, 513-522.	6.3	13
11	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2021, 77, 559-571.	2.8	31
12	Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines® Heart Failure Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e018696.	3.7	23
13	Rate of Progression of Aortic Stenosis in Patients With Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 644264.	2.4	2
14	Cardiovascular Toxicities of Androgen Deprivation Therapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 47.	3.0	20
15	Geographical Differences in Cardiovascular Comorbidities and Outcomes of COVID-19 Hospitalized Patients in the USA. <i>Cardiology</i> , 2021, 146, 481-488.	1.4	1
16	In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo. <i>Annals of Internal Medicine</i> , 2021, 174, JC69.	3.9	1
17	Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 1725-1735.	7.1	51
18	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, e23-e106.	0.8	33

#	ARTICLE	IF	CITATIONS
19	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1329.	6.1	64
20	Obesity and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 345-356.	2.1	9
21	Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 61.	4.8	8
22	Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. <i>Redox Biology</i> , 2021, 47, 102132.	9.0	17
23	COVID-19 myocarditis and long-term heart failure sequelae. <i>Current Opinion in Cardiology</i> , 2021, 36, 234-240.	1.8	26
24	Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 734820.	2.4	2
25	Senescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 763930.	2.4	30
26	Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , 2021, 144, 1521-1523.	1.6	44
27	Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. <i>Open Heart</i> , 2021, 8, e001849.	2.3	8
28	Modern Radiotherapy and Risk of Cardiotoxicity. <i>Chemotherapy</i> , 2020, 65, 65-76.	1.6	27
29	An overview of a different type of cardio-oncology gathering: summary of the COMP (cardio-oncology multidisciplinary practice) meeting held in Houston Texas, January 2020. <i>Cardio-Oncology</i> , 2020, 6, 20.	1.7	1
30	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, e159-e240.	2.8	364
31	In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization. <i>Annals of Internal Medicine</i> , 2020, 173, JC51.	3.9	0
32	Cardio-Oncology: Learning From the Old, Applying to the New. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 601893.	2.4	5
33	COVID-19 and Cardiovascular Health Among Patients with Cancer. <i>Current Cardiology Reports</i> , 2020, 22, 171.	2.9	8
34	Iron deficiency and iron therapy in heart failure and chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 508-514.	2.0	7
35	Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014669.	3.7	19
36	Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy. <i>JACC: Case Reports</i> , 2020, 2, 2095-2100.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. <i>International Journal of Obesity</i> , 2020, 44, 1561-1567.	3.4	26
38	Spirolactone in pulmonary arterial hypertension: results of a crossover study. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	1.7	22
39	Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1682-1690.	1.1	63
40	Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2020, 13, e006513.	3.9	154
41	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	3.7	240
42	Classification of Pulmonary Hypertension in CKD. <i>American Journal of Kidney Diseases</i> , 2020, 75, 690-692.	1.9	0
43	Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. <i>International Journal of Cardiology</i> , 2020, 313, 1-8.	1.7	16
44	Readmissions after Acute Kidney Injury during Left Ventricular Assist Device Implantation Hospitalization. <i>American Journal of Nephrology</i> , 2020, 51, 172-181.	3.1	7
45	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 113-120.	1.4	10
46	BASELINE RIGHT VENTRICULAR FUNCTION IS ASSOCIATED WITH REDUCED NEED OF DIURETICS IN PATIENTS WITH HEART FAILURE WITH IMPROVED EJECTION FRACTION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 786.	2.8	0
47	Acute Kidney Injury With Ventricular Assist Device Placement: National Estimates of Trends and Outcomes. <i>American Journal of Kidney Diseases</i> , 2019, 74, 650-658.	1.9	10
48	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , 2019, 140, e294-e324.	1.6	342
49	Understanding by General Providers of the Echocardiogram Report. <i>American Journal of Cardiology</i> , 2019, 124, 296-302.	1.6	1
50	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	5.2	232
51	Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e879-e886.	1.6	41
52	Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , 2019, 25, 380-400.	1.7	122
53	Heart Failure With Reduced Ejection Fraction and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2905-2907.	2.8	2
54	Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004817.	2.2	2

#	ARTICLE	IF	CITATIONS
55	Ularitide in Acute Heart Failure. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 17-23.	1.5	1
56	Prevention of "Failure". <i>Circulation</i> , 2018, 137, 106-108.	1.6	9
57	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2527-2536.	2.8	56
58	De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. <i>American Journal of Kidney Diseases</i> , 2018, 72, 223-233.	1.9	6
59	Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. <i>Population Health Management</i> , 2018, 21, 209-216.	1.7	30
60	Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2018, 14, 525-535.	2.1	9
61	Trends in Left Ventricular Assist Device Implantation and Associated Mortality Among Patients With and Without ESRD. <i>American Journal of Kidney Diseases</i> , 2018, 72, 620-622.	1.9	7
62	Do Biomarkers Improve Short-term Risk Prediction of Global Cardiovascular Events in Older Adults? Insights from the Atherosclerosis Risk in Communities Study*. <i>Journal of Clinical Lipidology</i> , 2018, 12, 525-526.	1.5	0
63	In AF and HF, catheter ablation vs medical therapy reduced mortality and hospitalization for worsening HF. <i>Annals of Internal Medicine</i> , 2018, 168, JC55.	3.9	1
64	NT-proBNP-guided and conventional therapies did not differ for readmission or mortality in acute decompensated HF. <i>Annals of Internal Medicine</i> , 2018, 169, JC21.	3.9	1
65	Myocardial Injury, Obesity, and the Obesity Paradox. <i>JACC: Heart Failure</i> , 2017, 5, 56-63.	4.1	19
66	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. <i>International Journal of Cardiology</i> , 2017, 233, 61-66.	1.7	42
67	Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine. <i>American Journal of Cardiology</i> , 2017, 119, 2030-2034.	1.6	17
68	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2016, 118, 1144-1149.	1.6	39
69	Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. <i>Clinical Cardiology</i> , 2016, 39, 145-149.	1.8	22
70	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e535-e578.	1.6	285
71	Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e579-e646.	1.6	532
72	Review: In HF with reduced EF, nurse-led titration of HF drugs reduces hospitalizations and mortality. <i>Annals of Internal Medicine</i> , 2016, 164, JC41.	3.9	1

#	ARTICLE	IF	CITATIONS
73	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity. <i>Circulation</i> , 2016, 133, 631-638.	1.6	96
74	Complex antithrombotic therapy: determinants of patient preference and impact on medication adherence. <i>Patient Preference and Adherence</i> , 2015, 9, 1657.	1.8	11
75	Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 111-121.	2.8	63
76	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2015, 36, 939-945.	2.2	82
77	Transitions of Care in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 384-409.	3.9	206
78	Response to Letter Regarding Article, "Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction". <i>Circulation: Heart Failure</i> , 2015, 8, 840-840.	3.9	3
79	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
80	Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 533-541.	3.9	64
81	Coronary Artery Disease Performance Measures and Statin Use in Patients With Recent Percutaneous Coronary Intervention or Recent Coronary Artery Bypass Grafting (from the NCDR PINNACLE Registry). <i>American Journal of Cardiology</i> , 2015, 115, 1013-1018.	1.6	4
82	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015, 8, 1052-1058.	3.9	70
83	Provider Type and Quality of Outpatient Cardiovascular Disease Care. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1803-1812.	2.8	54
84	Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2015, 115, 21-26.	1.6	134
85	Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 123-130.	3.9	134
86	Relation Between Playing Position and Coronary Artery Calcium Scores in Retired National Football League Players. <i>American Journal of Cardiology</i> , 2014, 114, 1836-1840.	1.6	11
87	Pre-Morbid Body Mass Index and Mortality After Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2743-2749.	2.8	83
88	Prognostic Significance of Hyponatremia Among Ambulatory Patients With Heart Failure and Preserved and Reduced Ejection Fractions. <i>American Journal of Cardiology</i> , 2014, 113, 1834-1838.	1.6	67
89	SAFETY AND EFFECTIVENESS OF BALLOON AORTIC VALVULOPLASTY FOR SEVERE AORTIC STENOSIS IN THE CONTEMPORARY ERA. <i>Journal of the American College of Cardiology</i> , 2014, 63, A1746.	2.8	0
90	Differential Response to Low Dose Dopamine or Nesiritide in Patients with Acute Heart Failure and Renal Dysfunction in Accordance to LV EF: Sub-Group Analysis of the ROSE AHF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, S94.	1.7	0

#	ARTICLE	IF	CITATIONS
91	Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension. <i>JACC: Heart Failure</i> , 2014, 2, 412-421.	4.1	58
92	Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. <i>International Journal of Cardiology</i> , 2014, 172, 239-241.	1.7	18
93	Effects of Spironolactone Treatment in Elderly Women With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2014, 20, 560-568.	1.7	38
94	Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 3741-3746.	1.7	52
95	Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk in the Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2013, 59, 1802-1810.	3.2	82
96	Worsening renal function is not associated with response to treatment in acute heart failure. <i>International Journal of Cardiology</i> , 2013, 167, 1912-1917.	1.7	23
97	Incident Cancer in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 887-888.	2.8	6
98	Recurrent low-level Troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. <i>International Journal of Cardiology</i> , 2013, 166, 394-398.	1.7	23
99	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1268.	7.4	976
100	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	7.4	410
101	Association Between Preoperative Diuretic Use and In-hospital Outcomes After Cardiac Surgery. <i>Cardiovascular Therapeutics</i> , 2013, 31, 291-297.	2.5	12
102	Classification of Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation: Heart Failure</i> , 2012, 5, 152-159.	3.9	278
103	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 653-659.	3.9	107
104	Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2296-2304.	27.0	790
105	New Insights into Mechanisms of Action of Carvedilol Treatment in Chronic Heart Failure Patients: A Matter of Time for Contractility. <i>Journal of Cardiac Failure</i> , 2012, 18, 183-193.	1.7	24
106	Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research Network. <i>Journal of Cardiac Failure</i> , 2012, 18, 176-182.	1.7	91
107	Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2012, 59, 998-1005.	2.8	578
108	Echocardiographic Changes During Treatment of Acute Decompensated Heart Failure: Insights From the ESCAPE Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 792-798.	1.7	35

#	ARTICLE	IF	CITATIONS
109	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure – A Pilot Study. <i>Journal of Obesity & Weight Loss Therapy</i> , 2012, 02, 1-8.	0.1	19
110	Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 233-240.	1.9	15
111	Obesity, Leptin, and Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1878-1880.	2.8	10
112	Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship. <i>American Heart Journal</i> , 2011, 161, 567-573.	2.7	60
113	Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). <i>Journal of Cardiac Failure</i> , 2011, 17, 634-642.	1.7	171
114	Lack of Association of Changes in BNP with Cardiorenal Syndrome during Treatment of Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, S91.	1.7	0
115	Digoxin treatment in heart failure – Unveiling risk by cluster analysis of DIG data. <i>International Journal of Cardiology</i> , 2011, 150, 264-269.	1.7	19
116	Diuretic Strategies in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 364, 797-805.	27.0	1,363
117	New Predictive Models of Heart Failure Mortality Using Time-Series Measurements and Ensemble Models. <i>Circulation: Heart Failure</i> , 2011, 4, 456-462.	3.9	31
118	Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 53-58.	3.9	172
119	Biomarkers of inflammation in heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 331-341.	3.9	169
120	Comparison of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Among Those With Versus Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2010, 105, 373-377.	1.6	81
121	Mortality After Hospitalization for Heart Failure in Blacks Compared to Whites. <i>American Journal of Cardiology</i> , 2010, 105, 694-700.	1.6	18
122	A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. <i>International Journal of General Medicine</i> , 2010, 3, 279.	1.8	80
123	The Potentially Modifiable Burden of Incident Heart Failure Due to Obesity: The Atherosclerosis Risk in Communities Study. <i>American Journal of Epidemiology</i> , 2010, 172, 781-789.	3.4	30
124	Predicting Quality of Life in Veterans with Heart Failure: The Role of Disease Severity, Depression, and Comorbid Anxiety. <i>Behavioral Medicine</i> , 2010, 36, 70-76.	1.9	27
125	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. <i>Vascular Health and Risk Management</i> , 2010, 6, 449-55.	2.3	6
126	Impact of Alpha 1-Adrenergic Antagonist Use for Benign Prostatic Hypertrophy on Outcomes in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2009, 104, 270-275.	1.6	22

#	ARTICLE	IF	CITATIONS
127	Reduction in BNP Levels With Treatment of Decompensated Heart Failure and Future Clinical Events. <i>Journal of Cardiac Failure</i> , 2009, 15, 293-299.	1.7	55
128	Hemoglobin Drop during Hospitalization Predicts Poor Survival in Anemic Patients with Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, S97-S98.	1.7	0
129	Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2009, 54, 422-428.	2.8	171
130	Depression and Anxiety in Ambulatory Patients With Heart Failure. <i>Psychosomatics</i> , 2009, 50, 592-598.	2.5	15
131	Treatment of patients with heart failure and preserved ejection fraction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 516-528.	0.9	4
132	Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2008, 51, 415-426.	2.8	144
133	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 1-14.	2.2	20
134	The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes. <i>American Journal of Surgery</i> , 2008, 196, 720-725.	1.8	43
135	Decreasing Body Temperature Predicts Early Rehospitalization in Congestive Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 489-496.	1.7	21
136	The Metabolic Syndrome and Mortality in an Ethnically Diverse Heart Failure Population. <i>Journal of Cardiac Failure</i> , 2008, 14, 590-595.	1.7	12
137	Advances in the treatment of heart failure with a preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2008, 23, 233-240.	1.8	7
138	Translation of clinical trial results into practice: Temporal patterns of β -blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. <i>American Heart Journal</i> , 2007, 153, 515-522.	2.7	29
139	β -Blockers in systolic heart failure: Do physicians need more courage?. <i>American Heart Journal</i> , 2007, 154, e25.	2.7	0
140	Statin Use and Survival in Patients with Ischemic and Non-Ischemic Heart Failure: Results of a Meta-Analysis. <i>Journal of Cardiac Failure</i> , 2007, 13, S78.	1.7	0
141	Anti-angiotensin Therapy: New Perspectives. <i>Cardiology Clinics</i> , 2007, 25, 573-580.	2.2	11
142	The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients With Diabetes Mellitus and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 32-36.	2.8	33
143	Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. <i>American Heart Journal</i> , 2006, 152, 348-354.	2.7	61
144	Comparison of Morbidity in Women Versus Men With Heart Failure and Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2006, 97, 1228-1231.	1.6	78

#	ARTICLE	IF	CITATIONS
145	Diastolic dysfunction and diastolic heart failure: Mechanisms and epidemiology. <i>Current Cardiology Reports</i> , 2005, 7, 178-183.	2.9	33
146	Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 502-503.	3.3	0
147	Obesity as a prognostic factor in chronic symptomatic heart failure. <i>American Heart Journal</i> , 2005, 150, 1233-1239.	2.7	77
148	Role and Optimal Dosing of Angiotensin-Converting Enzyme Inhibitor Therapy. <i>Heart Failure Clinics</i> , 2005, 1, 25-37.	2.1	0
149	Variation by race in factors contributing to heart failure hospitalizations. <i>Journal of Cardiac Failure</i> , 2005, 11, 23-29.	1.7	16
150	Long-Term Results of Coronary Artery Bypass Grafting in Patients With Ischemic Cardiomyopathy: The Impact of Renal Insufficiency and Noncardiac Vascular Disease. <i>Journal of Cardiac Failure</i> , 2005, 11, 206-212.	1.7	8
151	Review: B-type natriuretic peptide consistently predicts death and cardiovascular events in heart failure. <i>ACP Journal Club</i> , 2005, 143, 53.	0.1	0
152	Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction**The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.. <i>American Journal of Cardiology</i> , 2004, 94, 1003-1007.	1.6	34
153	Aldosterone receptor blockers in the treatment of heart failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 327-334.	0.9	6
154	Impact of race on health care utilization and outcomes in veterans with congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 778-784.	2.8	108
155	Circulating Levels of Tumor Necrosis Factor Correlate With Indexes of Depressed Heart Rate Variability. <i>Chest</i> , 2003, 123, 716-724.	0.8	80
156	Angiotensin-Receptor Blockade in Acute Myocardial Infarction â€” A Matter of Dose. <i>New England Journal of Medicine</i> , 2003, 349, 1963-1965.	27.0	46
157	Perils of the Random Experiment. <i>American Journal of Therapeutics</i> , 2003, 10, 112-121.	0.9	0
158	New Therapeutics for Chronic Heart Failure. <i>Annual Review of Medicine</i> , 2002, 53, 59-74.	12.2	60
159	The fragility of cardiovascular clinical trial results. <i>Journal of Cardiac Failure</i> , 2002, 8, 247-253.	1.7	6
160	Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2002, 8, 390-398.	1.7	97
161	Asymptomatic left ventricular dysfunction: an overlooked part of the continuum of heart failure. <i>Heart Failure Monitor</i> , 2002, 3, 42-8.	0.7	0
162	Effects of Vesnarinone on Peripheral Circulating Levels of Cytokines and Cytokine Receptors in Patients With Heart Failure. <i>Chest</i> , 2001, 120, 453-459.	0.8	17

#	ARTICLE	IF	CITATIONS
163	Trials within Trials. Contemporary Clinical Trials, 2001, 22, 605-619.	1.9	29
164	Cytokines and Cytokine Receptors in Advanced Heart Failure. Circulation, 2001, 103, 2055-2059.	1.6	903
165	Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure. Circulation, 1999, 99, 3224-3226.	1.6	367
166	An overview of tumor necrosis factor $\hat{\pm}$ and the failing human heart. Current Opinion in Cardiology, 1999, 14, 206.	1.8	77
167	Quantification of the Myocardial Response to Low-Dose Dobutamine Using Tissue Doppler Echocardiographic Measures of Velocity and Velocity Gradient. American Journal of Cardiology, 1998, 81, 615-623.	1.6	145
168	The role of cytokines in disease progression in heart failure. Current Opinion in Cardiology, 1997, 12, 218-223.	1.8	79
169	CARDIAC INVOLVEMENT IN SCLERODERMA. Rheumatic Disease Clinics of North America, 1996, 22, 841-860.	1.9	93